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Abstract 
Introduction Type 2 diabetes is common, affecting over 400 million people 
worldwide. Risk of serious complications can be reduced through use of effective 
treatments and active self-management. However, people are often concerned about 
starting new medicines and face difficulties in taking them regularly. Use of brief 
messages to provide education and support self-management, delivered through 
mobile phone-based text-messages can be an effective tool for some long-term 
conditions. We have developed messages aiming to support patients’ self-
management of type 2 diabetes in the use of medications and other aspects of self-
management, underpinned by theory and evidence. The aim of this trial is to 
determine the feasibility of a large-scale clinical trial to test the effectiveness and 
cost-effectiveness of the intervention, compared to usual care. 
Methods and analysis The feasibility trial will be a multi-centre individually 
randomised, controlled trial in primary care recruiting adults (≥35 years) with type 2 
diabetes in England. Consenting participants will be randomised to receive short 
text-messages three times a week with messages designed to produce change in 
medication adherence or non-health related messages for six months. The aims are 
to test recruitment methods, retention to the study, the feasibility of data collection 
and the mobile-phone and web-based processes of a proposed definitive trial and to 
refine the text messaging intervention. The primary outcome is the rate of 
recruitment to randomisation of participants to the trial. Data, including patient 
reported measures, will be collected online at baseline and the end of the six-month 
follow-up period. With 200 participants (100 in each group), this trial is powered to 
estimate 80% follow up within 95% confidence intervals of 73.8% to 85.3%. The 
analysis will follow a pre-specified plan.  
Ethics and Dissemination Ethics approval was obtained from the West of Scotland 
Research Ethics Committee 05. The results will be disseminated through conference 
presentations, peer-reviewed journals and will be published on the trial website: 
www.summit-d.org 
SuMMiT-D (SUpport through Mobile Messaging and digital health Technology for 
Diabetes) 
Trial Registration 
ISRCTN13404264; date of registration 10 October 2018 
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Article Summary 
Strengths and limitations of this study 
1.  The use of brief messages to support self-management and provide 
motivation and education, delivered through mobile phone-based text-
messages can be an effective tool for some long-term conditions. 
2.  There are a few trials testing the impact of brief messaging in type 2 
diabetes; although some have systematically-developed messages mapped 
to theoretical constructs, many are at risk of bias and may be limited in their 
application to specific contexts.  
3. The objective of the SuMMiT-D Feasibility trial is to test recruitment and 
randomisation of participants, and collection of proposed primary and 
secondary outcome data in planning for a large, outcomes based, 
randomised controlled trial. 
4. The messages evaluated in this study are (i) targeted at constructs identified as 
being related to medication adherence by systematic reviews of the literature, 
and (ii) demonstrated to have fidelity to intended behaviour change techniques 
(as rated by experts) and acceptability to target population (as rated by patients) 
5.  Potential mechanisms for the action of the brief messages will be assessed 
through changes in constructs that are related to medication-taking 
behaviour, questions based on the Technology Acceptance model, and self-
report medication adherence. 
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Introduction 
 
Type 2 diabetes is one of the most common long-term conditions affecting 422 
million people worldwide1 and 4.7 million people in the UK.2 It can lead to major 
complications including cardiovascular disease, renal failure and neuropathy.3  The 
global burden of diabetes is projected to reach up to 2.2% of global gross domestic 
product,4  and many of these costs are due to preventable complications. Prevention 
includes the use of treatments of proven efficacy5,6 alongside supporting self-
management.7 However, concerns about medicines and difficulties in taking them 
regularly, whether intentional or unintentional, are common8 and lead to poor 
diabetes control and increased use of health resources.9 The cost of non-adherence 
to diabetes medication in the United Kingdom has been estimated at £100 million per 
year in avoidable treatment costs.10  A wide range of services are available to 
support people in better use of their medicines, but evidence of their effectiveness 
and cost-effectiveness is weak. 11 These services are often targeted at particular 
groups of individuals and are frequently designed as "one-off" interventions. 
Examples include medication reviews, education and addressing cost issues. 12 
Understanding and improving this situation could make a major contribution to health 
and health-care costs.  
Systematic reviews do not provide strong evidence to support the wider use of 
current approaches to developing interventions to improve adherence.13 Brief 
messages delivered at a wide scale and low cost via digital health systems added to 
usual care have been shown to be effective in improving health for some conditions 
and are a promising approach to the problem.14  
Systematic reviews of text messages to support patients to adhere to treatment, 
and of mobile health interventions in diabetes, identify some effective interventions. 
There are a few trials testing the impact of brief messaging in type 2 diabetes; 
although some have systematically-developed messages mapped to theoretical 
constructs, many are at risk of bias and may be limited in their application to specific 
contexts.14,15 Recent trials of text-messaging for cardiovascular risk prevention and 
blood pressure lowering have shown clinically relevant changes in outcomes 
compared with usual care.16,17  
In addition, there is substantial evidence that tailored interventions are more 
effective than generic interventions.18 Tailored interventions may be seen by 
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recipients as more personally relevant, so they will be more likely to attend to, read, 
understand, and act on them. In addition, tailored interventions are designed to 
change determinants of the target behaviour that are relevant to particular individuals 
or to small subgroups of individuals; they therefore more precisely target the 
determinants of the individual’s behaviour. 
SuMMiT-D (SUpport through Mobile Messaging and digital health Technology for 
Diabetes) is a programme of work comprised of three phases: formative work, a 
feasibility trial and a large scale, effectiveness randomised controlled trial of a mobile 
phone-based system intended to deliver brief, tailored, behaviour-change messages 
to people with type 2 diabetes focusing on use of medication. The intervention is 
intended to focus on a broad range of individuals with type 2 diabetes, but those with 
younger onset diabetes and using insulin alone were not included, as these features 
can require care using different pathways. In the formative work for this trial, we 
identified theoretical constructs and features of intervention content found to be 
associated with medication adherence in patients with type 2 diabetes and mapped 
these onto a standard taxonomy for behaviour change techniques (BCTs), that is, 
active ingredients of interventions used to promote behavioural change.19,20.  We 
then developed a large set of messages to target each BCT, and examined which 
types of messages are most useful and easy to understand for people starting and 
taking an oral diabetes medicine, and the extent to which it might be helpful for 
patients to decide on the types of messages they want to receive. We received input 
from approximately 300 patients with type 2 diabetes and healthcare professionals 
caring for this patient population. Preliminary findings of this trial development work 
were used to develop this feasibility trial with scope for further refinement of the 
system for the main clinical trial. 
The primary objective of the SuMMiT-D Feasibility trial is to test recruitment and 
randomisation of participants to the trial. We will test collection of planned primary 
and secondary outcome data in planning for a large, outcomes-based, randomised 
controlled trial. We will assess the feasibility and acceptability of the intervention for 
patients and healthcare professionals; the willingness of participants to be 
randomised; follow-up rates; resource use and trial procedures. We will also carry 
out a process evaluation of how the system is used and refine the way it is 
embedded within usual care. Potential mechanisms for the action of the brief 
messages will be assessed through changes in hypothesised health psychology 
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constructs relating to use of medication, self-report medication adherence,21 and 
questions based on the Technology Acceptance model.22  
Methods and analysis 
The SuMMiT-D Feasibility trial protocol is reported according to SPIRIT and 
EMERGE recommendations.23,24 
Patient and Public Involvement 
Patient members of the public are integral to this trial. A panel of eleven patient and 
public involvement (PPI) members with type 2 diabetes was set up and continues to 
inform our work, reviewing all patient documentation and research findings, and 
supports the development of the intervention. 
All patient facing documents for the SuMMiT-D feasibility trial, including, the 
participant information sheet, informed consent form, posters, user guides, and 
website were reviewed by PPI panel members. The panel has been kept up to date 
with frequent trial updates in the form of an email newsletter, also published on the 
trial website (www.summit-d.org). The results of the study will be made available to 
trial participants, PPI panel members and participating GP practices on the trial 
website. 
Trial Design 
SuMMiT-D Feasibility is a primary care based, two-arm, individually randomised 
controlled, parallel group trial aiming to recruit a total of 200 patients across twenty 
general practice sites in England. Patients with type 2 diabetes will be randomly 
allocated to receive an individually tailored Short Messaging System (SMS) text-
messaging based intervention for 26 weeks that aims to encourage and support 
them in developing a habit of taking their medication as intended (that is, to promote 
effective implementation of dosing and treatment continuation)25 and provides hints 
and tips to help them with other aspects of living with the condition alongside usual 
care (treatment arm), or to usual care with the addition of infrequent non-health 
related messages (control arm) (Figure 1).  
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Intervention 
Intervention arm: Condition-specific tailored text messaging system and usual care 
Participants assigned to the intervention group will receive brief health related SMS 
text messages, based on systematic review of the evidence identifying determinants 
of medication taking behaviour.20 Messages were developed based on systematic 
review evidence by experts,20 and were refined in an iterative process of ensuring 
acceptability based on patient feedback and demonstration of fidelity to intended 
behaviour change determinants, as rated by an independent group of experts.26 A 
more detailed description of the intervention is given in the accompanying TIDieR 
checklist. Examples of messages are given in the supplementary file (Appendix 1).  
The intervention is a digital health system with the following components: 
i. Participants will be sent up to four automated text-messages per week with an 
average frequency of three per week relating to diabetes management and use of 
medicine.  
ii. The library of text-messages uses different behaviour change techniques to 
target health-related behaviour change relating to use of medicines, as well as 
messages targeting other aspects of diabetes care (including diet and exercise). 
iii. The types of messages sent will be tailored to participants based on time since 
starting new glucose, blood pressure and cholesterol-lowering medication and 
current smoking status. 
iv. Frequency of messages received using a particular group of behaviour change 
techniques can be modified based on a participant's response to individual 
messages received through sending a text-message in response to a particular 
message. Participants may incur a cost for sending messages in response 
depending on their network plan.  
v. The style of messages will be patient-centred and will encourage patients to seek 
further relevant information (including the use of links where possible to selected 
external websites e.g. Diabetes UK).  
Control arm: Usual care and one non-health-related message a month 
Participants assigned to usual care will receive non-health related text-messages at 
a frequency of approximately one every four weeks. Care will otherwise not differ 
from usual care.  
Outcomes 
The primary outcome is the rate of recruitment to randomisation of participants to the 
trial. Details of outcomes and measurement are shown in Table 1. We will measure 
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recruitment against planned recruitment rates for the proposed main trial and 
number of people showing an interest in the trial and not proceeding or those who 
withdraw from the control group and give a reason. 
Secondary outcomes (Table 1) focus on feasibility of collection of clinical and 
economic measurement data for the proposed main trial. They include the availability 
of HbA1c, systolic blood pressure and total to HDL cholesterol ratio data from medical 
records, retention rates, and proportion of prescribing data available. A self-report 
questionnaire will assess: medication adherence,21 health status with the EQ-5D-
5L,27 resource use for the health economic analysis, technology acceptance,22 and 
constructs targeted by SMS and hypothesised to mediate the effects of the 
intervention on adherence.28  
Procedures and assessments 
Participants who express interest in taking part in the trial will be screened by the 
trial team and will consent and submit their baseline questionnaires either online or 
on paper according to their preference. Participants will be randomised by the trial 
team and will receive messages for 26 weeks from randomisation to final follow-up. 
All participants will be asked to complete the same set of questionnaires at baseline 
and at the end of their 26-week follow-up period. Medical notes reviews will be 
conducted at baseline, six- and 18-months from randomisation.  
Recruitment 
Potential participants will be identified through general practices in England. 
Participating practices fall under four Clinical Research Networks (CRNs): Thames 
Valley & South Midlands, Greater Manchester, West Midlands and South West 
Peninsula.  
Healthcare professionals will screen their type 2 diabetes clinic lists and will invite 
eligible patients. Patients will receive an invitation letter and summary information 
leaflet. Eligible patients may also be contacted by phone, email or text by the 
practice team up to three times.  
Expressions of interest 
People interested in taking part can send their full name by SMS text-message to the 
trial team to register their interest. If potential participants have any difficulties in 
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registering their interest in the trial, they will also be able to contact the team via 
phone or email and will receive support in registering as required.  
Screening assessment 
Following an expression of interest, further information about the study will be 
provided by email or by post as requested. Eligibility will be confirmed by phone. 
Inclusion criteria 
Eligible participants are ≥35 years of age, taking oral glucose lowering treatment, 
blood pressure lowering treatment or lipid-lowering treatment either alone or in 
combination. They have access to a mobile phone and are able, if necessary, with 
help (e.g. relative, friend, neighbour), to send, understand and retrieve brief SMS 
text-messages in the English language. Participants who are using insulin treatment 
without also concomitant use of oral glucose lowering treatment; who are pregnant, 
within three months post-partum or planning pregnancy during the course of the trial; 
have a serious medical condition that, in the opinion of the investigator, makes them 
ineligible; have been admitted to hospital within the last three months for hyper- or 
hypoglycaemia, are ineligible.  
Informed consent   
Participants will provide consent either on-line or on paper.  
Baseline and follow up assessments 
The following questionnaires will be administered (online or by post) at the baseline 
assessment: the Medication Adherence Report Scale (MARS) self-report scale,21 the 
EuroQol 5-Dimension, 5-Level (EQ-5D-5L) scale,27 a set of measures developed for 
the study based on the technology acceptance model,22 and a healthcare utilisation 
record to allow healthcare resource use to be costed. A further set of measures 
assess the constructs that will be targeted by the BCTs within the messages.  These 
constructs are hypothesised to mediate the effects of the intervention on medication 
taking behaviour, in line with the logic model we have developed based on the 
Health Action Process Approach (Figure 2, Table 1 and Appendix 3).28   
All self-report data will be collected either online or on paper according to the 
participant’s preference. The same measures are collected at 26 weeks after 
randomisation alongside clinical record data. 
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Randomisation  
Participants will be randomised after consent and when all baseline assessments 
have been completed. Participants will be allocated in a 1:1 ratio to either the 
intervention or the control arm. Randomisation will be done using a validated secure 
web-based randomisation programme (Sortition) provided by the University of 
Oxford Primary Care Clinical Trials Unit (PC-CTU). Allocation will be carried out with 
a non-deterministic minimisation algorithm to ensure groups are balanced for 
important baseline prognostic and other factors: study site, age (<65/≥65 years), 
gender (male/female), duration of diabetes (<5 years/≥5 years), number of 
medications (<5/≥5). The allocated intervention will be implemented directly by the 
platform on which the digital health system is run. Apart from the qualitative research 
team and the engineering team, allocation is blinded to all other trial and healthcare 
staff. Due to the nature of the study, unblinding is not required during the trial. 
Discontinuation of intervention or withdrawal from trial 
Participants can withdraw from the trial at any time. Participants can also choose to 
Pause or Stop receipt of text messages by sending a text-message or contacting the 
trial office by telephone or post. Adverse events are collected, and serious 
unexpected adverse events related to the intervention are determined by the chief 
investigator and reported in line with local procedures.  
Statistical Analysis  
Power 
With 200 participants (100 in each group) the feasibility trial is powered to estimate 
80% follow up within 95% confidence intervals of 73.8% to 85.3%. 
Analysis 
The primary outcome will be the number of patients recruited to randomisation as a 
proportion (with 95% confidence interval) of the target recruitment number. 
Secondary outcomes will be reported overall and separately by allocated arm.   
An intention-to-treat approach will be used for an exploratory analysis of 
secondary outcomes by allocated arm. Continuous outcomes will be analysed using 
an analysis of covariance adjusting for minimisation factors. Results will be 
presented as an adjusted difference in means with 95% confidence interval.  Binary 
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outcomes will be analysed in a similar way using log binomial regression models 
(adjusting for minimisation factors). Results will be presented as relative risks with 
95% confidence intervals.  There will be no formal assessment of treatment efficacy 
for this feasibility study. 
Analysis of utility and costs 
Data collected on healthcare utilisation will be assessed for completeness. The items 
recorded include patient contacts with healthcare professionals, use of primary care 
services, hospital outpatient appointments, accident and emergency visits, and 
inpatient stays, prescribed and purchased medications, and personal social services. 
The proportion of complete and returned questionnaires will be reported. Total costs 
associated with each item of resource will be estimated based on unit costs from 
standard sources,29,30 and presented descriptively.  
The costing is conducted from the perspective of the NHS and therefore the cost 
to the patient is not considered, we will however, estimate costs of responding to text 
messages using estimates from average network tariffs and data collected on the 
quantity of digital information transmitted. 
Responses to the EQ-5D-5L questionnaire will also be examined for 
completeness and reported by proportion of returned questionnaires and items with 
a valid response. Health utility values corresponding to patients’ EQ-5D-5L profiles 
will be calculated by mapping the 5L descriptive system data onto the 3L value set,31 
and presented descriptively. 
Process evaluation 
We will perform a mixed-methods process analysis, consisting of a qualitative 
element and a quantitative element. The qualitative process evaluation will examine 
the experience of participants and health professionals in their use of and 
implementation of the messaging system. Longitudinal interviews with up to 30 
participants will take prior to use of the system and after the 26-week follow-up. 
Additionally, up to 30 healthcare professionals will be invited to share their 
experiences of taking part in this trial.  
Interviews with trial participants 
Participants who consent to taking part in the embedded qualitative study will be 
purposefully selected by characteristics including age, gender, length of time of 
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diabetes and type of medication, and invited to share their views on engagement 
with and content of the messaging system, and to provide insight into how it was 
implemented in daily life, identify issues around potential attrition and inform final 
procedures for the main trial.  
Interviews and/or focus groups with healthcare professionals  
Healthcare staff from practices taking part in the trial will be invited to take part in 
focus groups or qualitative interviews to share their experience of recruiting for this 
trial, and how the intervention was implemented in routine clinical care. Eligible staff 
will be those with a potential role in the implementation of a text-message system or 
who have contact with patients with type 2 diabetes. These will include GPs, practice 
nurses, receptionists and healthcare assistants. 
Analysis of qualitative data: trial participants 
Thematic analysis will be used inductively to identify key issues, focussing on 
similarities and differences identified in themes to understand the issues that are 
important to the participants.32 We will use NVivo and mind-mapping software to 
code data, identify themes and interpret these and their relationship. The data 
analysis will be inductive. 
Analysis of qualitative data: healthcare professionals 
We will follow a semi-structured topic guide based on the core constructs of 
extended normalization process theory (NPT):33 Coherence, Reflexive Monitoring, 
Cognitive Participation and Collective Action to ensure key areas are covered while 
allowing flexibility to follow up topics introduced by participants. NVivo software will 
be used to facilitate data organisation, analysis and the development of themes. The 
analysis will use a thematic approach informed by NPT.32 
Quantitative process analysis 
To facilitate understanding of mechanism of the intervention, the effect of the 
intervention on the set of measures based on the logic model (Figure 2 and Table1) 
will be analysed using a per-protocol analysis for responders, according to allocated 
group. This will identify if these measures have been affected by the intervention.  A 
further analysis will examine how these measures in the logic model (controlling for 
baseline) predict change in self-reported medication adherence using hierarchical 
multiple regression techniques.34  This analysis will thereby assess extent of 
association between measures in the logic model and self-reported medication 
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adherence.35 These analyses will be used in conjunction with the qualitative 
analyses described above to inform decisions about selection of SMS messages 
relating to particular BCTs, and potentially refinement of the logic model and 
selection of measures for the full trial. Receipt of messages on participants’ mobile 
phones will be monitored throughout the trial.  
Data Management  
All trial data will be entered on electronic case report forms. The clinical database is 
built on REDCap (Research Electronic Data Capture), a secure, web-based 
application designed to support data capture for research studies.36  
Ethics and dissemination 
The trial will be conducted according to the principles of the Declaration of Helsinki 
and in accordance with other relevant national guidelines, regulations, acts and 
using Good Clinical Practice guidelines. The University of Oxford sponsors the trial. 
The protocol, informed consent form, participant information leaflet and all other 
patient-facing material have been submitted and approved by the West of Scotland 
Research Ethics Committee 05 (HRA ref: 18/WS/0173). The role of the Trial Steering 
Committee is taken on by the NIHR Programme Steering Committee. 
Dissemination plan 
The results of this trial will be submitted to a peer reviewed journal for publication. 
 
Recruitment to the SuMMiT-D Feasibility Study began with the first participant 
randomised on 26 November 2018 and the last participant randomised on 16th April 
2019. Reporting of the trial is anticipated in the first quarter of 2020.  
Discussion 
SuMMiT-D Feasibility will inform the design of a future large-scale randomised 
controlled trial, aiming to estimate the clinical and cost effectiveness of the text-
messaging intervention and identify difficulties that might be encountered in practice. 
If effective and implemented in the NHS, this intervention could help reduce the 
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burden of complications and increased costs associated with non-adherence. This 
research could also offer a model for technology-based self-management support 
that could be extended to other aspects of diabetes care and other long-term 
conditions.  
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Data 
Dissemination 
A manuscript with the results of the primary outcome will be published in a peer-
reviewed journal. Additional manuscripts will report secondary outcomes and be 
submitted for publication in peer-reviewed journals.  
Data availability 
Data will be available from the main trial following completion of the analysis 
specified in the trial statistical analysis plan on request from the trial data repository 
(www.SuMMiT-D.org).   
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Figure 1 
Trial Profile 
 
 
Figure 2 
Logic model 
 
Title: Logic model showing anticipated mechanisms of action in the SuMMIT-D Feasibility 
study, based on the Health Action Process Approach  
 
(a) Footnote: (a) This construct includes both beliefs about the necessity of taking 
medication, and concerns about taking that medication. 
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Table 1 
Schedule of trial outcomes and measures 
Outcome Measure Timing (months) 
  
0 6  18  
Participant recruitment to the trial.  Recruitment against planned recruitment rates.  x   
Participant willingness to be randomised.  
Number of people showing an interest and not proceeding or those who withdraw from the 
control group and give a reason  
x  
 
Feasibility of collection of clinical measurement data for the proposed 
clinical trial. 
Retrieval of measurements of HbA1c, systolic blood pressure and cholesterol for trial 
participants from medical record. 
x x 
 
Willingness of participants to be followed up over the 26-week period 
post randomisation. 
Retention and follow-up rates  x 
 
Feasibility of collection of prescribing data on trial participants.  
Proportion of medication possession ratio for glucose, blood pressure and lipid lowering 
medication obtainable from prescribing data in participant’s medical record 
 x 
 
Feasibility of collecting self-reported questionnaire measures.  
Proportion of completed self-reported measures (Demographics and additional information 
Questionnaire; MARS self-report scale; EQ-5D-5L Health status questionnaire; Healthcare 
Utilisation Record Questionnaire (cost measurement); Health psychology and technology 
acceptance questionnaire. 
x x 
 
Feasibility of collecting medical history and baseline medication from 
medical record 
Proportion of data obtained x  
 
Feasibility and acceptability of the intervention for patients and 
healthcare professionals (including general practitioners, nurses, 
receptionists and pharmacists). Qualitative process evaluation 
Data obtained through focus groups, qualitative interviews with patients and healthcare staff.  x x 
 
Assess reliability of measures of hypothesised mechanism of action, 
and sensitivity to change in response to receipt of SMS messages.  
Examine relationship between these measures and self-reported 
adherence, as preliminary process analysis.. (Quantitative process 
evaluation) 
Change in quantitative mechanism of action measures and relationship between changes in 
these measures and self-reported adherence.  
x x 
 
Changes in clinical measurement data  HbA1c, systolic blood pressure and cholesterol for trial participants from medical record. x x x 
Information on message delivery and interaction with participants.  Automated reports from messaging service on messages delivered and interactive messaging  x x 
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